Effect of sevelamer on aortic pulse wave velocity in patients on hemodialysis: a prospective observational study.
Aortic stiffening and aortic calcification are risk factors for cardiovascular events in hemodialysis (HD) patients, and these 2 risk factors are interrelated. Sevelamer decreases aortic calcification but its effect on aortic stiffness has not been investigated previously. Thirteen HD patients commencing sevelamer treatment and 13 matched controls were followed for 11 months. Aortic pulse wave velocity (PWV), augmentation index (AIx), and levels of inhibitors of vascular calcification (fetuin-A, matrix-GLA-protein, osteoprotegerin/RANKL) were measured at baseline and at the end of follow-up, and the differences between the groups were compared. Determinants of the changes in PWV during follow-up were assessed by multivariate linear regression. At baseline, PWV was 9.93 (2.10) m/s in sevelamer-treated patients and 9.20 (2.84) m/s in control patients (p=0.464). By the end of follow-up, PWV decreased by 0.83 (2.3) m/s in sevelamer-treated patients while it increased by 0.93 (1.88) m/s in controls (p=0.042). The direction of changes in AIx were similar, but not statistically significant. There were no significant differences in the levels of inhibitors of calcification either at baseline or during follow-up. In multivariate linear regression sevelamer treatment, diabetes, heart rate, and C-reactive protein were related to the change in PWV. These data suggest that sevelamer treatment is associated with an improvement in aortic stiffness in HD patients, but it does not seem to affect serum levels of inhibitors of vascular calcification.
Othmane
Taha El Hadj
Tel H
1st Department of Medicine, Semmelweis University, 2/a Korányi S, Budapest, Hungary.
Bakonyi
Geza
G
Egresits
Jozsef
J
Fekete
Bertalan Cs
BC
Fodor
Erzsebet
E
Jarai
Zoltan
Z
Jekkel
Csaba
C
Nemcsik
Janos
J
Szabo
Andras
A
Szabo
Tamas
T
Kiss
Istvan
I
Tisler
Andras
A
D001783:Blood Flow Velocity / Q000187:drug effects; D002114:Calcinosis / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011073:Polyamines / Q000008:administration & dosage / Q000494:pharmacology*; D011446:Prospective Studies; D011673:Pulsatile Flow / Q000187:drug effects*; D006435:Renal Dialysis / Q000379:methods; D000069603:Sevelamer; D014655:Vascular Resistance / Q000187:drug effects*
D011073:Polyamines; D000069603:Sevelamer